| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Long-Term Growth Targets
McKesson continues to strengthen its portfolio of differentiated assets and capabilities, advancing health outcomes for all. The company remains well-positioned to capture long-term growth opportunities through disciplined execution of its strategic priorities and sustained operational momentum.
McKesson is updating its long-term growth targets and introducing segment-specific targets for the new reporting structure. McKesson is also updating and increasing its long-term Adjusted Earnings per Diluted Share growth target to 13% to 16%, an increase from the prior range of 12% to 14%. This reflects the strength of McKesson's leading platforms in oncology, multispecialty, and biopharma solutions, supported by operating leverage and efficient capital deployment.
Posted In: MCK
